Trials / Terminated
TerminatedNCT00310232
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Ontario Clinical Oncology Group (OCOG) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The general objective of this study is to improve the Quality of Life (QoL) of selected patients with advanced carcinoma of the lung. The specific objective is to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and underlying anemia of malignancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epoetin Alfa |
Timeline
- Start date
- 2001-02-01
- Completion
- 2004-04-01
- First posted
- 2006-04-03
- Last updated
- 2024-04-02
Locations
15 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00310232. Inclusion in this directory is not an endorsement.